Jan 5, 2021 · The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.

Since the 1980s, MSK Kids doctors have treated children with neuroblastoma with an antibody called 3F8. It attaches to neuroblastoma cells and helps focus a patient’s own immune system — especially white blood cells — on attacking neuroblastoma cells. Conventional 3F8 is …

3F8 is a murine IgG3 [1] monoclonal antibody which binds to GD2. [2] It has been used in the detection and treatment of neuroblastoma. [3] For imaging neuroblastoma, it is labelled with one of the radioisotopes iodine-124 and iodine-131. [4] [5]

Sep 28, 2018 · Naxitamab is a humanized form of the mouse antibody 3F8. Beginning in the late 1980s, MSK investigators used 3F8 in combination with surgery and chemotherapy to treat neuroblastoma. This method significantly improved cure rates for children with high-risk disease.

Dec 1, 2018 · To decrease immunogenicity, hu3F8, a humanized anti-GD2 antibody, was constructed. Objective: To find the maximum-tolerated dose of hu3F8 with granulocyte-macrophage colony-stimulating factor.

Factual information about the purpose and scientific aspects of 3F8 treatment, and its role in various frontline, refractory, or relapse treatments, will be discussed elsewhere in this Handbook. The focus of this section is coping with the side effects of 3F8 treatment.

Non-conventional methods included immunoscintigraphy using 3F8 radiolabeled with iodine-131 (131 I-3F8), bone marrow immunocytology, and molecular detection of the residual neuroblastoma marker GAGE by reverse transcriptase polymerase chain reaction (RT-PCR) in the bone marrow.

Naxitamab (previously called humanized 3f8 or hu3F8), a humanized GD2‐binding monoclonal antibody (mAb), 5 is approved in the USA for use in combination with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) for the treatment of patients with R/R HR neuroblastoma limited to bone and/or BM who have demonstrated a partial response ...

3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts).

A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2.